Income Statement (Annual)

ATRS / Antares Pharma, Inc. Short Interest

ATRS / Antares Pharma, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Revenues
  Sales Revenue Goods Net 3,507 5,774 7,630 9,138 10,958 13,196 27,533 40,318 41,695
  Licensing And Development Revenue - - - - - - - - -
  Royalty Revenue 603 2,062 3,145 3,874 4,672 2,351 1,991 1,503 1,649
  Revenues 8,311 12,819 16,458 22,576 20,618 26,502 45,658 52,222 54,515
Cost Of Revenue
  Cost Of Goods Sold 1,813 2,799 3,623 6,117 6,990 9,359 12,925 23,909 22,317
  Contract Revenue Cost - 1,474 3,174 3,404 2,207 1,877 6,533 4,908 5,149
  Cost Of Revenue 4,140 4,273 6,797 9,520 9,197 11,237 19,458 28,817 27,466
Gross Profit 4,171 8,545 9,661 13,055 11,421 15,265 26,200 23,405 27,049
Operating Expenses
  Research And Development Expense 7,902 8,803 6,699 14,922 15,263 18,638 19,731 21,127 13,147
  Selling General And Administrative Expense - - - 9,585 17,008 31,740 26,931 26,395 30,353
  Operating Expenses 13,865 14,572 14,098 24,507 32,272 50,378 46,662 47,522 43,500
Operating Income Loss -9,694 -6,026 -4,437 -11,452 -20,850 -35,113 -20,462 -24,117 -16,451
Interest Expense -633 -4 -1 - - - - - 1,423
Other Nonoperating Income Expense - -65 49 24 -59 -90 -22 -122 271
Net Income Loss -10,291 -6,091 -4,388 -11,427 -20,507 -35,152 -20,659 -24,339 -16,743
Earnings Per Share Basic And Diluted - - -0 -0 -0 -0 -0 -0 -0
Weighted Average Number Of Share Outstanding Basic And Diluted - - 96,995 110,185 126,897 130,550 146,594 154,992 156,054

Peers - Surgical and Medical Instruments and Apparatus (3841)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 036642106